Usefulness of a flow chart for targeted screening of congenital cytomegalovirus-related hearing loss

J Neonatal Perinatal Med. 2018;11(3):339-343. doi: 10.3233/NPM-17110.

Abstract

Around 90% of congenital cytomegalovirus infected neonates are asymptomatic at birth. Among the infected infants showing no clinical abnormalities, 7 to 15% or over may develop sensorineural hearing loss and only about 50% of these cases are detectable at birth. In 2013, the Neonatal Intensive Care Unit at Maggiore Hospital in Bologna (Italy) introduced a one-page flow chart aimed at identifying neonates with unapparent congenital cytomegalovirus infection by means of selective cytomegalovirus screening of patients who failed to pass a hearing screening test. Since its introduction, 83 infants have been referred to our clinic for sample collection and two cases of congenital cytomegalovirus-related sensorineural hearing loss were diagnosed and treated at the appropriate time.

Keywords: Cytomegalovirus; congenital infection; sensorineural hearing loss; targeted screening.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use
  • Cytomegalovirus / pathogenicity
  • Cytomegalovirus Infections / congenital*
  • Cytomegalovirus Infections / diagnosis*
  • Cytomegalovirus Infections / drug therapy
  • Cytomegalovirus Infections / transmission
  • Early Diagnosis
  • Evoked Potentials, Auditory, Brain Stem / drug effects
  • Female
  • Hearing Loss, Sensorineural / diagnosis*
  • Hearing Loss, Sensorineural / drug therapy
  • Hearing Loss, Sensorineural / physiopathology
  • Hearing Loss, Sensorineural / virology*
  • Humans
  • Infant, Newborn
  • Neonatal Screening / methods*
  • Pregnancy
  • Pregnancy Complications, Infectious / diagnosis*
  • Pregnancy Complications, Infectious / drug therapy
  • Pregnancy Complications, Infectious / physiopathology
  • Pregnancy Complications, Infectious / virology*
  • Recovery of Function
  • Treatment Outcome
  • Valganciclovir / therapeutic use

Substances

  • Antiviral Agents
  • Valganciclovir